

Malignant Hematology Areas of Interest

(Investigator Initiated Studies and Research Collaborations)

REGN1979 (CD20xCD3) odronextamab

Non-interventional proposals:

- Investigating tumor and immune correlates of response to CD20xCD3 bispecific antibodies in B-NHL

Interventional proposals:

- Novel treatment combinations, including combinations with novel agents targeting non-redundant pathways, in all lines of therapy for the treatment of b-NHL.
- Sequencing Odronextamab in the treatment paradigm for the treatment of B-NHL
- Investigating Odronextamab in hard-to-treat, medically unaddressed, and rare populations with B-Cell malignancies in high unmet medical needs for treatment.
- Alternative regimens, including new outpatient administration and outpatient monitoring protocols that may alleviate patient logistical barriers to treatment.
- Predictors of response and/or (primary or acquired) resistance to Odronextamab in the treatment of b-NHL

(5.0, 27Feb2024)

REGN5458 (BCMA x CD3 bispecific antibody) livoseltamab

Clinical Interventional proposals:

- Multiple Myeloma
 - Novel treatment combinations
 - Unique sequencing strategies (e.g. optimization of BCMA retreatment, post GPRc5D bsAb)
 - Optimization of treatment administration (e.g. outpatient administration/monitoring, alternative dosing frequency and fixed duration, retreatment prior to progression)
 - Characterization and management of adverse events
 - Exploration in special patient subpopulations of high unmet need
 - Elucidation of resistance or relapse mechanisms
- Other plasma cell dyscrasias
- Non-plasma cell dyscrasia BCMA targetable hematologic malignancies

(v5.0, Oct2024)

Regeneron is currently accepting proposals for Investigator Initiated Studies and Research Collaborations for the Malignant Hematology Products in the United States (US) and the European Union (EU).